ArticleProceedings of the National Academy of Sciences of the United States of America1993
CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 86 citations in OpenAlex.
- CD43 expressed in Sertoli, Leydig and germ cells inhibits testicular function and represents a potential target to treat male infertility or effect male contraception.Reproductive biology and endocrinology : RB&E · 2025Article
- Apoptosis-mediated ADAM10 activation removes a mucin barrier promoting T cell efferocytosis.Nature communications · 2024Article
- ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface.The Journal of biological chemistry · 2020Article
- SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.BMC bioinformatics · 2017Review
- Engagement of distinct epitopes on CD43 induces different co-stimulatory pathways in human T cells.Immunology · 2016Article
- Hypoxia: The Force that Drives Chronic Kidney Disease.Clinical medicine & research · 2016Review
- Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy.British journal of cancer · 2014Article
- Aberrant glycosylation as biomarker for cancer: focus on CD43.BioMed research international · 2014Review
- Role of O-glycosylation and expression of CD43 and CD45 on the surfaces of effector T cells in human T cell leukemia virus type 1 cell-to-cell infection.Journal of virology · 2012Article
- Downhill running in rats: influence on neutrophils, macrophages, and MyoD+ cells in skeletal muscle.European journal of applied physiology · 2003Article
- Reduced CD43 expression on the neutrophils of MDS patients correlates with an activated phenotype of these cells.International journal of hematology · 2001Article
- Identification of polymorphonuclear leukocyte and HL-60 cell receptors for adhesins of Streptococcus gordonii and Actinomyces naeslundii.Infection and immunity · 2000Article
- CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA.Nucleic acids research · 2000Article
- An antiserum raised against the recombinant cytoplasmic tail of the human CD43 glycoprotein identifies CD43 in many mammalian species.Immunology · 1999Article
- CD43, a molecule with multiple functions.Immunologic research · 1999Review
- Membrane protein secretases.The Biochemical journal · 1997Review
- Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis.The EMBO journal · 1996Article
- CD43 is a murine T cell costimulatory receptor that functions independently of CD28.The Journal of experimental medicine · 1995Article
- Human thymic epithelial cells express an endogenous lectin, galectin-1, which binds to core 2 O-glycans on thymocytes and T lymphoblastoid cells.The Journal of experimental medicine · 1995Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
CD43, the major sialoglycoprotein of human leukocytes, whose expression is defective in patients with the Wiskott-Aldrich syndrome, was down-regulated by phorbol 12-myristate 13-acetate (PMA) on granulocytes but not on lymphocytes. However, CD43 expressed on both of these leukocyte subpopulations was down-regulated after crosslinking by anti-CD43 monoclonal antibodies, a stimulation that may simulate the effect of a natural CD43 ligand. Soluble, labeled CD43 molecules were isolated from culture supernatants of both surface-iodinated granulocytes activated by PMA and lymphocytes stimulated with anti-CD43 antibodies. Thus, in this case down-regulation represents release from the cell surface into the culture medium, rather than internalization. The apparent molecular masses of the released molecules and of soluble CD43 isolated from human serum were identical. Importantly, PMA-induced down-regulation of CD43 on granulocytes was markedly blocked both by the metalloprotease inhibitor 1,10-phenanthroline and by the serine protease inhibitors N alpha-(p-tosyl)-L-lysine chloromethyl ketone and Pefabloc SC, which inhibit two different classes of proteases, thus indicating that the release is proteolytic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.